RBC Capital lowered the firm’s price target on Maravai Lifesciences (MRVI) to $5 from $7 and keeps an Outperform rating on the shares after its Q2 earnings miss. With the new management in place and FY25 guidance suspended however, Maravai is on a path to rationalizing its cost structure, starting with $50M in cost actions with aims to return to adjusted EBITDA positive by the second half of FY26, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- Maravai Lifesciences price target lowered to $5 from $10 at Craig-Hallum
- Maravai Lifesciences: Strategic Shift Amid Mixed Results Warrants Hold Rating
- Maravai LifeSciences Announces Restructuring Amid Revenue Decline
- Maravai Lifesciences reports Q2 adjusted EPS (8c), consensus (7c)
- Maravai Lifesciences withdraws FY25 guidance